Vitae Pharmaceuticals (VTAE) : Net money flow in Vitae Pharmaceuticals (VTAE) was negative ($4.93 million) and the inflow of money on uptick was $0.22 million, whereas, the outflow of money on downticks amounted to $5.15 million on Monday. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.04. The block trades show that the large investors, were aggressive sellers in the stock. On the other hand, the total value of block trades done on downticks was $4.93 million. The money flow in block trades was negative ($4.93). Vitae Pharmaceuticals (VTAE) gained $0.03 cent during the day and reached $8.63, a gain of 0.35% over the previous day.
Vitae Pharmaceuticals, Inc. has lost 3.41% in the last five trading days and dropped 12.38% in the last 4 weeks. Vitae Pharmaceuticals, Inc. is up 17.38% in the last 3-month period. Year-to-Date the stock performance stands at -51.49%.
Vitae Pharmaceuticals (NASDAQ:VTAE): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $8.90 and $8.64 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.06. The buying momentum continued till the end and the stock did not give up its gains. It closed at $8.78, notching a gain of 1.74% for the day. The total traded volume was 148,910 . The stock had closed at $8.63 on the previous day.
In a related news,The director of Vitae Pharmaceuticals, Inc, Hayden Donald J Jr sold 16,130 shares at $7.42 on March 21, 2016. The Insider selling transaction had a total value worth of $119,685. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform. The Company has two partnered product candidates in the clinic and several wholly owned drug candidates in preclinical development. The Companys two partnered product candidates are VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes, and BI 1147560 for the treatment and prevention of Alzheimers disease. The Companys several wholly owned product candidates advancing in preclinical development, including VTP-43742 for the treatment of autoimmune disorders, VTP-38543 for the treatment of atopic dermatitis and VTP-38443 for the treatment of acute coronary syndrome.